Mayo Clinic Cancer Center | Strategic Alliance Partners

March 04, 2021

Tanios S. Bekaii-Saab, MD, FACP, discusses the toxicity differences between regorafenib and trifluridine/tipiracil in colorectal cancer.

March 01, 2021

Yttrium-90 glass microspheres administered in a personalized, dosimetric approach demonstrated a 16-month improvement in overall survival compared with a standard dosimetric approach in patients with unresectable hepatocellular carcinoma.

February 27, 2021

Targeted therapies have helped to improve responses in patients with relapsed chronic lymphocytic leukemia regardless of high-risk disease, although optimal sequencing and toxicity management need to be further explored to strengthen the utilization of these options.

February 26, 2021

Tanios S. Bekaii-Saab, MD, FACP, shares his approach for treating patients with HCC across several lines of therapy, as well as factors to consider when making sequencing decisions.

February 23, 2021

Joleen M. Hubbard, MD, discusses identifying disease progression in patients with colorectal cancer.

February 18, 2021

Kabir Mody, MD discusses new directions with yttrium-90 glass microspheres in hepatocellular carcinoma as demonstrated in the retrospective LEGACY study.